IPOs/Nasdaq/2026/Oak Hill Bio Inc.
Oak Hill Bio Inc. OAKH
Oak Hill Bio Inc. (OAKH) priced its IPO on Nasdaq on November 4, 2026 at $10.00 a share. Clinical-stage biopharmaceutical company developing gene therapies for rare pediatric diseases. Based in New York, New York.
Offer price
$10.00
Raised
Not given
Shares offered
9,098,529 shares
Lock-up
180 days
The company
Oak Hill Bio Inc. is a clinical-stage biopharmaceutical company developing gene therapies for rare pediatric diseases, based in New York, New York. It sold 9,098,529 shares at $10.00 each in the offer.
The proceeds will fund research and development expenses and working capital and general corporate purposes. After the offer, Michael F. MacLean holds 1.5% and Timothy J. Miller holds 1.5%.
Where the money goes
Research and development expenses
Working capital and general corporate purposes
Revenue and results
Revenue, 2024$0
Revenue, 2023$0
Net result, 2024loss of $12.3 million
Net result, 2023loss of $8.7 million
The risks it lists first
No products approved or commercialized
Substantial doubt about ability to continue as going concern